For a pharmaceutical company preparing for a potential acquisition, ESG due diligence is no longer a peripheral exercise. Environmental, social and governance factors can influence how an acquirer evaluates operational resilience, regulatory exposure, supply-chain risk, reputation, compliance and long-term value.
A pharmaceutical business may have strong financial performance and an attractive product portfolio, yet unresolved ESG issues can create additional questions during an acquisition review.
These issues can range from environmental liabilities and manufacturing practices to clinical-trial ethics, product access, employee practices, data governance, third-party risk and board oversight.
The difficulty is that ESG information is rarely held in one place. Relevant evidence can sit across regulatory filings, sustainability reports, quality systems, procurement records, clinical documentation, supplier assessments, legal materials and internal policies.
This is where enterprise decision intelligence platform can support preparation.
AI can help acquisition targets organise ESG evidence, identify information gaps, compare disclosures with industry expectations, monitor external risks and prepare management teams for likely acquirer questions.
The goal is not to automate the due diligence decision.
It is to create a more complete, traceable and decision-ready view of the company's ESG position before the acquirer begins its review.
What Is ESG Due Diligence in a Pharmaceutical Acquisition?
ESG due diligence is the process of evaluating environmental, social and governance factors that could affect a company's risk profile, operations, reputation or value.
For a pharmaceutical company, ESG considerations can extend beyond traditional sustainability reporting.
An acquirer may examine:
Environmental compliance
Energy and emissions
Water and waste management
Pharmaceutical manufacturing impacts
Supply-chain sustainability
Labour practices
Employee health and safety
Clinical-trial conduct
Patient safety
Product access and affordability
Data privacy
Responsible use of AI
Business ethics
Anti-bribery and corruption
Regulatory compliance
Board oversight
Risk management
The precise scope depends on the transaction, business model, geography, product portfolio and acquirer.
That means preparation should begin with the company's actual risk profile rather than a generic ESG checklist.
Why ESG Due Diligence Matters in Pharma M&A
Pharmaceutical companies operate in highly regulated and evidence-intensive environments.
An ESG issue can therefore have consequences beyond its immediate category.
For example, a supplier sustainability issue could become a supply-continuity concern.
A manufacturing environmental issue could create regulatory or remediation costs.
Weak clinical-trial governance could create reputational and compliance exposure.
Poor data governance could raise privacy or cybersecurity questions.
Weak oversight of third parties could create bribery, quality or regulatory risk.
This interconnectedness is why ESG should be considered alongside broader M&A due diligence rather than treated as a separate reporting exercise.
An acquirer is ultimately trying to understand:
What could create risk, cost, disruption or reputational damage after the transaction?
Step 1: Establish the ESG Due Diligence Scope
The first step is to determine what the potential acquirer is likely to examine.
Start by mapping the company's:
Then map ESG risks to those activities.
A pharmaceutical company with extensive manufacturing operations may have a different ESG risk profile from a research-focused biotech.
Likewise, a company operating across multiple jurisdictions may face different reporting, labour, environmental and governance expectations.
AI can help create an initial risk map by connecting business activities to relevant ESG themes.
The final scope should be confirmed by legal, compliance, ESG, finance and transaction teams.
Step 2: Build an ESG Evidence Inventory
The next step is to identify what evidence already exists.
Relevant information may include:
ESG or sustainability reports
Annual reports
Regulatory filings
Environmental permits
Site-level environmental data
Energy and emissions records
Waste records
Water-use information
Supplier assessments
Procurement policies
Human-rights policies
Employee policies
Health and safety records
Clinical-trial policies
Patient-safety procedures
Data-protection policies
Cybersecurity controls
Ethics and compliance policies
Board materials
Risk registers
Internal audit reports
Third-party assessments
The objective is to establish:
What does the company claim?
What evidence supports the claim?
Who owns the evidence?
Is the evidence current?
What remains missing?
This distinction is critical.
A policy document demonstrates that a policy exists.
It does not necessarily demonstrate effective implementation.
Step 3: Create an ESG Claims-to-Evidence Matrix
An acquirer may challenge ESG statements during diligence.
For every significant claim, create an evidence trail.
For example:
ESG Claim | Supporting Evidence | Owner | Status |
Supplier ESG screening is implemented | Supplier assessment records | Procurement | Complete |
Emissions are monitored | Site emissions data | Operations | Complete |
Employees receive compliance training | Training records | HR/Compliance | Complete |
Clinical research follows ethical standards | Clinical governance documentation | Medical Affairs | Review |
Data privacy controls are established | Privacy policies and audits | Legal/IT | Complete |
AI can help identify claims that appear unsupported or where evidence is fragmented.
This creates a more defensible position before an external review begins.
Step 4: Assess Pharmaceutical ESG Across the Value Chain
Pharmaceutical ESG should not be assessed only at corporate headquarters.
The value chain matters.
Consider:
Research → Clinical development → Manufacturing → Supply chain → Distribution → Patient
Each stage can create different ESG considerations.
Research and Development
Questions may include:
How are research ethics governed?
How is research data managed?
How are animal studies governed?
How are conflicts of interest managed?
Clinical Development
Consider:
Manufacturing
Potential areas include:
Energy use
Water consumption
Waste
Emissions
Environmental compliance
Worker safety
Process efficiency
Supply Chain
Review:
Supplier selection
Third-party screening
Human-rights risks
Environmental exposure
Geographic concentration
Business continuity
Commercial Operations
Consider:
Product access
Pricing policies
Ethical promotion
Patient support
Data privacy
Compliance
AI can help connect these areas into a single enterprise-level ESG risk map.
Step 5: Identify Environmental Exposure
Environmental diligence can become particularly important for pharmaceutical companies with manufacturing operations.
The target should understand its exposure across:
The company should also identify locations where environmental exposure could create transaction risk.
For each major facility, consider:
What is the environmental obligation?
What evidence demonstrates compliance?
Are there historical liabilities?
Are remediation activities ongoing?
Could climate or resource constraints affect operations?
AI can help compare facility-level information and flag missing documentation.
However, environmental conclusions should be validated by appropriate environmental and legal specialists.
Step 6: Review Social Risk
The social component of pharmaceutical ESG extends across employees, patients, communities and business partners.
Key areas may include:
For an acquirer, the key question is often whether social practices create material operational or reputational exposure.
AI can help consolidate evidence from multiple systems and identify recurring themes.
For example, repeated supplier assessment findings may indicate a broader third-party governance issue rather than isolated incidents.
Step 7: Examine Governance in Detail
Governance can be particularly important because it determines how ESG risks are identified, managed and escalated.
Review:
Board oversight
ESG accountability
Risk management
Compliance
Internal controls
Anti-bribery policies
Whistleblower systems
Data governance
Cybersecurity
AI governance
Third-party oversight
Audit processes
Executive accountability
The acquirer may want to understand not only whether policies exist, but whether governance mechanisms actually operate.
That means the target should be prepared to demonstrate:
Policy → Process → Control → Monitoring → Escalation → Evidence
AI can help map these relationships.
Step 8: Benchmark Against Pharmaceutical Peers
A target company should understand how its ESG position compares with relevant peers.
Benchmarking can cover:
This is an area where competitive intelligence in healthcare can complement ESG analysis.
AI can collect and organise publicly available information from comparable pharmaceutical companies to identify:
Common disclosures
Emerging expectations
Areas where competitors provide more evidence
Areas where the target may be ahead
Areas where the target may face questions
The purpose is not to copy competitors.
It is to understand the context in which an acquirer may evaluate the target.
Step 9: Identify ESG Gaps Before the Acquirer Does
One of the biggest benefits of AI-assisted due diligence preparation is early gap identification.
A gap may be:
Missing data
Outdated policy
Inconsistent disclosure
Unsupported ESG claim
Missing supplier assessment
Incomplete site information
Weak ownership
Poor documentation
Lack of historical records
Unclear remediation status
AI can compare the company's available evidence against a predefined diligence framework and create a prioritised gap register.
A useful classification is:
Critical
Could materially affect transaction risk or valuation.
High
Likely to attract detailed diligence questions.
Moderate
Should be addressed but may not materially affect the transaction.
Low
Documentation or process improvement opportunity.
This allows management to focus resources where they matter most.
Step 10: Prepare for Acquirer Questions
Do not wait for the data room to open before thinking about questions.
Build a simulated diligence question bank.
Potential questions could include:
Environmental
"What environmental liabilities exist at manufacturing sites?"
Supply chain
"How are ESG risks assessed among critical suppliers?"
Clinical
"How does the company govern ethical conduct across clinical programmes?"
Governance
"Who has executive responsibility for ESG risk?"
Data
"How are privacy and responsible AI risks governed?"
Workforce
"How does the company monitor employee health and safety?"
AI can generate potential questions based on the company's risk profile and public disclosures.
Subject-matter experts should then refine the questions and prepare responses.
Step 11: Create a Virtual Data Room Readiness Review
Before sharing documents with a potential acquirer, perform an internal readiness review.
Organise information into logical categories:
Environmental
Social
Governance
Board materials
Compliance policies
Risk registers
Audit reports
AI governance
Data governance
AI can help classify documents and identify missing evidence.
This reduces the risk of discovering important gaps only after the buyer starts asking questions.
Step 12: Establish Evidence Ownership
Every major ESG metric or claim should have an owner.
For example:
ESG Area | Primary Owner |
Emissions | Operations |
Environmental compliance | EHS/Legal |
Workforce | HR |
Clinical ethics | Clinical/Medical |
Patient safety | Pharmacovigilance/Quality |
Supplier ESG | Procurement |
Data privacy | Legal/Privacy |
Cybersecurity | IT/Security |
Governance | Legal/Compliance |
ESG reporting | Sustainability/Finance |
AI can help identify duplicated ownership or areas where no clear owner exists.
This matters because an acquirer may ask a detailed question that crosses multiple functions.
The company should know who can provide the authoritative answer.
Step 13: Use AI to Detect Disclosure Inconsistencies
Another practical application is comparing different corporate documents.
For example, an ESG report may describe a target differently from:
Annual reports
Website disclosures
Regulatory filings
Supplier policies
Internal documentation
AI can flag differences in:
Metrics
Dates
Targets
Definitions
Terminology
Scope
Reported progress
This allows the company to resolve inconsistencies before the buyer identifies them.
Step 14: Prepare a Management-Level ESG Narrative
Due diligence is not only about documents.
Management needs to explain the company's ESG position clearly.
A useful narrative should answer:
What are the company's material ESG risks?
What controls are in place?
What evidence demonstrates performance?
Where are the remaining gaps?
What remediation is underway?
Who is accountable?
How could the risks affect the business?
The objective is not to hide weaknesses.
It is to demonstrate that management understands them and has a credible plan.
Step 15: Link ESG Risks to Transaction Value
ESG due diligence becomes more useful when risks are translated into business implications.
For example:
Environmental risk → remediation cost → potential transaction liability
Supplier ESG risk → supply disruption → revenue exposure
Workforce issue → retention problem → operational impact
Compliance weakness → regulatory exposure → financial/reputational risk
Data governance weakness → privacy exposure → transaction risk
AI can help structure these relationships, but financial and legal teams should validate the actual valuation implications.
This moves ESG from a reporting exercise into a transaction-risk framework.
Step 16: Monitor New ESG and Regulatory Developments
ESG expectations continue to change across jurisdictions.
A transaction may take months to complete, so the target should monitor developments during the process.
Relevant intelligence may include:
ESG reporting requirements
Environmental regulation
Pharmaceutical manufacturing requirements
Supply-chain rules
Human-rights requirements
Data-protection developments
AI governance
Industry-specific sustainability expectations
An AI-enabled monitoring process can flag material changes and route them to the appropriate internal owner.
This is especially valuable when the company operates across multiple jurisdictions.
The challenge in ESG due diligence is rarely the absence of information.
It is the fragmentation of information.
A company may have thousands of documents but still struggle to answer a simple question:
"What evidence supports this ESG claim?"
An enterprise decision intelligence platform can help connect information across business functions and create a more structured view of evidence, risks, and decisions.
Pienomial's Life Sciences solution is designed to support intelligence workflows for life sciences organisations, helping teams connect research and evidence across complex business questions.
Its platform provides an environment for connecting enterprise information and AI-assisted workflows.
For research-heavy diligence processes, Knol AI can support research and synthesis, while Knol Composer can help transform validated research into structured outputs.
This type of workflow can support a process such as:
Source evidence → ESG issue → Risk assessment → Management response → Supporting documentation → Acquirer question
The technology does not replace ESG professionals, legal advisers or transaction teams.
It helps them work from a more connected evidence base.
A Practical Pharma ESG Due Diligence Checklist
Before an acquisition review begins, the pharmaceutical company should confirm:
ESG due diligence scope has been defined.
Material ESG risks have been identified.
Environmental data has been collected by site.
Environmental permits and liabilities have been reviewed.
Workforce and health-and-safety evidence is organised.
Clinical and patient-related governance has been documented.
Supplier ESG assessments are available.
Human-rights policies and controls are documented.
Governance responsibilities are clearly assigned.
Compliance and anti-bribery controls are documented.
Data privacy and cybersecurity controls have been reviewed.
AI governance has been assessed where relevant.
ESG claims have supporting evidence.
Public disclosures have been checked for consistency.
Peer benchmarks have been reviewed.
Material gaps have been prioritised.
Acquirer questions have been anticipated.
Data-room documentation has been organised.
Every major ESG area has a clear owner.
Management has a consistent ESG narrative.
Regulatory and ESG developments are being monitored.
Conclusion
Preparing a pharmaceutical company for ESG due diligence should begin well before a potential acquirer starts asking questions.
The strongest preparation combines evidence collection, risk assessment, peer benchmarking, documentation, governance and management readiness.
AI can make that process substantially more efficient.
With pharma ESG due diligence AI, teams can search large evidence collections, identify gaps, compare peer disclosures, map claims to supporting documentation, simulate acquirer questions and monitor changing regulatory expectations.
But AI should remain an intelligence layer rather than the final decision-maker.
The most effective approach is:
Collect evidence → connect ESG risks → identify gaps → validate with experts → prepare management responses → monitor changes.
For pharmaceutical companies, ESG due diligence is ultimately about more than demonstrating sustainability performance.
It is about showing a potential acquirer that the company understands its environmental, social and governance exposures, has appropriate controls in place, can substantiate its claims, and knows where further work is required.
That level of preparedness can make the diligence process more transparent and help management respond to buyer questions with evidence rather than assumptions.
